SPY319.34+8.04 2.58%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%

Aimmune Therapeutics Q1 EPS $(1.030) Beats $(1.180) Estimate, Sales $575.000K Miss $1.340M Estimate

Aimmune Therapeutics (NASDAQ:AIMT) reported quarterly losses of $(1.030) per share which beat the analyst consensus estimate of $(1.180) by 12.71 percent. This is a 37.33 percent decrease over losses of $(0.750) per

Benzinga · 05/11/2020 20:24

Aimmune Therapeutics (NASDAQ:AIMT) reported quarterly losses of $(1.030) per share which beat the analyst consensus estimate of $(1.180) by 12.71 percent. This is a 37.33 percent decrease over losses of $(0.750) per share from the same period last year. The company reported quarterly sales of $575.000 thousand which missed the analyst consensus estimate of $1.340 million by 57.09 percent.